ADC Therapeutics (ADCT) Net Cash Flow (2023 - 2026)

ADC Therapeutics has disclosed Net Cash Flow across 4 years of filings, most recently posting -$30.3 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$30.3 million, up 46.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.2 million (up 191.09% YoY), and the FY2025 annual result was $10.2 million, up 136.77% from the prior year.
• Net Cash Flow came in at -$30.3 million for Q1 2026 at ADC Therapeutics, down from $26.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $69.7 million in Q2 2025 to a low of -$56.3 million in Q1 2025.
• The 4-year median for Net Cash Flow is -$26.1 million (2024), against an average of -$7.4 million.
• Across the five-year window, Net Cash Flow sank 176.98% in 2024 and soared 215.45% in 2025, its largest moves.
• ADC Therapeutics' Net Cash Flow stood at -$32.0 million in 2023, then rose by 27.84% to -$23.1 million in 2024, then jumped by 215.45% to $26.6 million in 2025, then slumped by 213.9% to -$30.3 million in 2026.
• The last three Net Cash Flow figures came in at -$30.3 million (Q1 2026), $26.6 million (Q4 2025), and -$29.8 million (Q3 2025), per Business Quant data.